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Abstract

Author Manuscript

The cholinergic anti-inflammatory pathway is an efferent vagus nerve-based mechanism that
regulates immune responses and cytokine production through α7nicotinic-acetylcholinereceptor
(α7nAChR) signaling. Decreased efferent vagus nerve activity is observed in inflammatory bowel
disease (IBD). We determined whether central activation of this pathway alters inflammation in
mice with colitis and the mediating role of a vagus nerve-to spleen circuit and α7nAChR
signaling. Two experimental models of colitis were used in C57BL/6 mice. Central cholinergic
activation induced by the acetylcholinesterase inhibitor galantamine or a muscarinic acetylcholine
receptor agonist treatments resulted in reduced mucosal inflammation associated with decreased
MHC II level and pro-inflammatory cytokine secretion by splenic CD11c+ cells mediated by
α7nAChR signaling. The cholinergic anti-inflammatory efficacy was abolished in mice with
vagotomy, splenic neurectomy or splenectomy. In conclusion, central cholinergic activation of a
vagus nerve–to spleen circuit controls intestinal inflammation and this regulation can be explored
to develop novel therapeutic strategies.
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Introduction

Author Manuscript

Inflammatory bowel diseases (IBD), consisting of Crohn’s disease (CD) and ulcerative
colitis (UC), are characterized by a chronic relapsing and remitting course as a result of
intestinal inflammation1. The release of inflammatory mediators, including proinflammatory cytokines from immune cells mediate tissue injury and exacerbation of IBD2.
Accordingly, several therapeutic approaches targeting inflammatory cytokines in IBDs have
been investigated3. Cholinergic signaling along the vagus nerve has been shown to control
interleukin (IL)-6, -1β, tumor necrosis factor (TNF)-α and other pro-inflammatory cytokine
production in different inflammatory conditions including IBD4–6. α7 nicotinic
acetylcholine receptors (α7nAChR) on macrophages, monocytes and mast cells have been
shown to mediate cholinergic anti-inflammatory output7, 8. This regulation is a part of the
current working model of the “inflammatory reflex” controlling immune responses and
cytokine levels9. In this model afferent vagus neurons sensing peripheral inflammatory
molecules convey the signal to the brain9. Consequent activation of efferent vagus neurons
results in increased cholinergic α7nAChR-dependent anti-inflammatory output and
suppressed pro-inflammatory cytokine release. Recent findings have suggested a role for the
splenic nerve and the spleen in this cholinergic anti-inflammatory pathway8.

Author Manuscript

IBD is associated with an autonomic imbalance and up to 35% of patients with UC exhibit
autonomic dysfunction with impaired efferent vagus nerve activity10. Although current
animal models do not sufficiently recapitulate IBD, we have previously reported that the
vagus nerve has a tonic inhibitory role on acute inflammation in murine models of colitis
mimicking UC (dextran sulfate sodium (DSS) model) and CD (2, 4 Dinitrobenzenesulfonic
acid (DNBS) model)4. In this context, the absence of the vagus nerve worsened acute DSS
and DNBS-colitis through a macrophage-mediated mechanism, associated with the release
of higher levels of IL-6, IL-1β and TNF-α, without affecting the level of the antiinflammatory cytokine IL-10. Electrical vagus nerve stimulation suppresses
myeloperoxidase activity (a marker of neutrophil infiltration) and TNF-α inflammatory
cytokine levels in experimental colitis and endotoxemia respectively11. Moreover, in line
with the role of α7nAChR in mediating anti-inflammatory cholinergic signals, it has been
demonstrated that smoking, ameliorates inflammation in UC patients12. Conversely,
smoking exacerbates inflammation in Crohn’s disease13, 12.

Author Manuscript

Dendritic cells (DCs) are key cells of the innate immune system that bridge innate with
adaptive immune responses. Strategically positioned in the lamina propria in proximity to a
number of luminal bacteria and antigenic stimuli, these cells perform a key role in activation
of the immune response and generation of gut inflammation via their passage into the spleen
and interaction with T cell4. Human studies have revealed that there is a significant increase
in the numbers of antigen presenting cell (APC), including DCs within the inflamed tissue
and the peripheral blood of patients with CD or UC15, 16. Furthermore, DCs depletion in
dextran sulfate sodium (DSS)-treated CD11c-DT receptor transgenic mice almost
completely inhibited experimental colitis17. Nicotinic receptors, including α7nAChR are
also expressed by human monocytes18 and mouse DCs19.
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The cholinergic anti-inflammatory pathway can be activated in the central nervous system
(CNS) by muscarinic acetylcholine receptor (mAChR) ligands or acetylcholinesterase
(AChE) inhibitors 20, 21. Galantamine (GAL) is a reversible, competitive AChE inhibitor,
which crosses the blood-brain barrier, increases brain cholinergic network activity22 and is
widely used in the treatment of Alzheimer’s disease. GAL activates efferent vagus nerve
activity23 and its anti-inflammatory activity has been associated with brain mAChRmediated activation of the cholinergic anti-inflammatory pathway21. In addition, it was very
recently demonstrated that a treatment with another centrally-acting cholinesterase
inhibitor–rivastigmine suppresses IL-6 levels and decreases the severity of murine DSS- and
TNBS-induced colitis24. A role for mAChRs in the CNS and macrophages in mediating the
effects of rivastigmine was also indicated.

Author Manuscript

Recent findings have highlighted a key role of the spleen in mediating vagus nerve antiinflammatory signaling during endotoxemia25. In the context of endotoxemia, the absence of
the intact vagus nerve or the spleen results in abrogation of the beneficial effect of the vagus
nerve activation. However, the implication of a vagus nerve-to spleen anti-inflammatory
axis in the regulation of intestinal inflammation remains to be determined. To provide
insight, here we studied whether central activation of the cholinergic anti-inflammatory
pathway by the AChE inhibitor GAL or mAChR ligands alters the severity of DSS-colitis
and the specific role of the spleen and DCs. We report that treatments with GAL or McNA-343 (a M1mAChR agonist) significantly ameliorate disease severity and inhibit
inflammation in the context of experimental colitis. These effects were entirely dependent
on vagus nerve and splenic nerve integrity and associated with inhibition of splenic CD11c+
cell pro-inflammatory cytokine production. In line with the importance of α7nAChRmediated signaling in the cholinergic regulation of inflammation, we found that direct
stimulation of DCs with a α7nAChR agonist decreases the release of pro-inflammatory
cytokines. Similar cholinergic anti-inflammatory mechanisms were demonstrated using the
DNBS-model, indicating the broader scope of our findings in the regulation of intestinal
inflammation.

Author Manuscript

Methods
Animals

Author Manuscript

Male C57BL/6 (7–9 weeks old) were purchased from Charles Rivers (Canada) and
maintained in the animal care facility at the University of Manitoba under specific pathogenfree conditions. No differences in food intake or body weight were observed between the
groups. All experiments were approved by the University of Manitoba animal ethics
committee (10-073) and conducted under the Canadian guidelines for animal research.
Induction of DSS and DNBS colitis
DSS (molecular weight [MW], 40 kilodaltons: ICN Biomedicals Inc) was added to the
drinking water in a final concentration of 5% (wt/vol) for 5 days26, 27. Controls were all
time-matched and consisted of mice that received normal drinking water only. Mean DSS
consumption was noted per cage each day. For the DNBS study, mice were anaesthetized
with Isoflurane (Abbott, Abbott Park, IL). A 10cm long PE-90 tubing (ClayAdam,
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Parsippany, NJ), attached to a tuberculin syringe, was inserted 3.5cm into the colon. Colitis
was induced by administration of 100Rl of 4mg of DNBS solution (ICN) in 50% ethanol
and left for 3 days28. Control mice (without colitis) received saline administration. Mice
with colitis were supplied with 6% sucrose in drinking water to prevent dehydration.
Surgical procedures and drug treatments

Author Manuscript

Mice were anaesthetized using ketamine (150 mg/kg, i.p) and xylazine (10 mg/kg, i.p). I.c.v.
implantation of the cannula, splenectomy (SPX), splenic neurectomy (NRX) or
subdiaphragmatic bilateral vagotomy (VXP) was performed on the same day4. In shamoperated group: mice implanted with the cannula received vehicle; mice were anaesthetized
and laparotomy performed but the spleen was not removed; splenic nerve was exposed but
not cut; vagal trunks were exposed but not cut, however, a pyloroplasty was performed. The
completeness of vagotomy was verified during post-mortem inspection of vagal nerve
endings using microscopic inspection associated with a Bielschowsky silver staining29. The
completeness of neurectomy was verified postmortem by noradrenaline enzyme-linked
immunosorbent assay in sham-operated and NRX animals. Mice were allowed to recover for
10 days. One day before initiation of colitis pharmacological treatments started: (GAL, 1–4
mg/kg/day, intraperitoneal (i.p.)); Huperzine-A: (H-A, 0.4 mg/kg/day, i.p., Sigma, Oakville,
ON); Atropine Methyl Nitrate (AMN, injected 20 min prior to GAL, 4 mg/kg/day, i.p.,
Sigma); Atropine sulfate (AS, injected 20 min prior GAL, 4 mg/kg/day, i.p. Sigma). Microosmotic pumps (Alzet, Cupertino, California, USA) were filled with vehicle (saline 0.2%),
M1 mAChR agonist McN-A-343 (Sigma) or M2 mAChR antagonist methoctramine (MTT,
5 ng/day, Sigma) solution and placed as previously described28.
Characterization of inflammation

Author Manuscript

Disease activity index (DAI) and macroscopic scores and colonic damage were determined
using a previously described scoring system for DSS colitis4, 30 and for DNBS4, 31 over 5
and 3 days respectively. Samples were collected 5 or 3 days post activation associated with
DSS or DNBS respectively and blood was collected by intracardiac puncture under
isoflurane anesthesia. Formalin-fixed colon segments coming from the splenic flexure were
stained with hematoxylin-eosin4. Colonic myeloperoxidase (MPO) activity was determined
following an established protocol32. Serum C-reactive protein (CRP) and colonic cytokine
levels were determined using ELISA commercial kit (R&D Systems, Minneapolis,
Minnesota, USA).
Acetylcholine detection

Author Manuscript

5 or 3 days post activation associated with DSS or DNBS respectively, the amount of
acetylcholine was measured using the acetylcholine assay kit (Amplex Red; Molecular
Probes). This kit measures the amount of hydrogen peroxide (which in the presence of
horseradish peroxidase leads to the oxidation of Amplex Red) produced through the
oxidation of choline. The concentration of choline and acetylcholine was determined using
the software provided by the manufacturer (KC4; Bio-Tek).
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Author Manuscript
Author Manuscript

5 or 3 days post activation associated with DSS or DNBS respectively, the spleens were
digested in 2mg/ml−1 collagenase D (Roche Diagnostics, Meylan, France) in RPMI 1640 for
30min at 37°C. EDTA at 5mM was added during the last 5min to disrupt DC–T cell
complexes, and the cell suspension was filtered. Total splenocytes after RBC lysis with
ACK lysis buffer (150mM NH4Cl, 10mM KHCO3, 0.1mM EDTA) were incubated with
CD11c+ microbeads (Miltenyi Biotec, Auburn, CA) for 15min at 48°C. The cells were then
washed, resuspended in cell separation buffer (Dulbecco’s Phosphate-Buffered Saline [DPBS] without Ca21 and Mg21 containing 2% FBS and 2mM EDTA, Life Technology) and
passed through magnetic columns for positive selection. After passing consecutively through
two columns, the collected splenic CD11c+ cell preparations showed greater than 95%
purity. splenic CD11c+ cell isolated from different groups of mice were cultured in complete
RPMI 1640 medium containing 10% heat-inactivated FBS, 25mg/ml−1 gentamicin, 2mM Lglutamine in 12-well plates at 1.10+6 cells/well for 24hrs, and the supernatants were
measured for IL-12p40, IL-6 and TNF-α by ELISA (R&D Systems).
In some experiments lipopolysaccharide (LPS, Sigma) was added to the cultures at a final
concentration of 100 ng/ml−1. In a separated set GAL or the a7nAChR agonist GST-21 were
added to medium at a final concentration of 10−6 M.
Flow cytometry

Author Manuscript

Surface staining of MACS isolated splenic CD11c+ cell (MHC II-Alexa 647, CD40-FITC,
CD86-PE, CD80-V450) (BD Biosciences) of different in vivo treatments were subjected to
standard multi-color flow cytometry procedures33. In brief, fluorescent-labeled antibodies
were added to the splenic CD11c+ cell (106) and incubated at 4 °C for 30 min in all surface
staining procedures. After excessive washing in flow buffer to remove unbound antibodies,
the cells were acquired in a BD FACS Calibur Flow Cytometer. Cell viability was assessed
using DAPI. Data analysis was performed using the Flowjo software.
Statistical analysis
Results are presented as means ±SEM. Statistical analysis was performed using one or two
way ANOVA followed by the Tukey-Kramer multiple comparisons post hoc analysis and a
p value of <0.05 considered significant with n=8 to 12 depending on the groups tested
(Prism 4, GraphPad).

Results
Author Manuscript

Centrally-acting acetylcholinesterase inhibitor treatment ameliorates the severity of colitis
Previous findings have characterized GAL as a central activator of the cholinergic antiinflammatory pathway23, 21, 34. Daily administration of GAL (1–4 mg/kg/day, i.p.), starting
one day before disease induction, dose-dependently reduced the severity of colitis (Figure
1A–D). GAL-treated mice with colitis showed a significantly lower DAI for the last 2 days
as compared to saline-treated controls with the disease (Figure 1A). This drug effect was
dose-dependent and the highest reduction was achieved with a dose of 4mg/kg/day, which
has been previously shown to inhibit mouse brain AChE activity by 43%34. The decreased
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severity of colitis in GAL (4 mg/kg/day)-treated mice as compared to saline–treated controls
was also further demonstrated by the 3.2-fold decrease in the macroscopic damage score, in
the 3.4-fold decrease in MPO activity and in the 1.25-fold decrease in serum CRP levels
(Figure 1B,C,D). GAL (4 mg/kg/day) treatment of mice with DSS-induced colitis also
significantly lowered the histological manifestation of the disease (Figure 2B, C, G).
Colonic IL-1β levels in GAL-treated mice were 4-fold lower as compared to the DSS-saline
treated group (Figure 3D). Accordingly, colonic IL-6 and TNF-α levels were 2- and 2.3-fold
lower (Figure 3E, F). No significant changes were detected for colonic IL-10
(Supplementary Figure 1A).

Author Manuscript

To characterize the specificity of brain AChE inhibition in preventing the development of
colitis, we utilized Huperzine-A (Hup A), a structurally distinct, highly selective, centrallyacting AChE inhibitor. Hup A administration (0.4 mg/kg/day, i.p.) significantly reduced the
disease severity and inflammation in mice with DSS-colitis (Supplementary Table 1, Figure
2D, G). In addition to their efficacy in DSS colitis, GAL and Hup A treatments decreased
the severity of DNBS colitis (Supplementary Figure 2). Taken together, these findings
indicate that centrally-acting AChE inhibitor treatments result in disease-alleviating and
counter-inflammatory effects in two experimental models of colitis.
Central muscarinic receptors are essential for alleviation of colitis and inhibition of colonic
inflammation by an acetylcholinesterase inhibitor

Author Manuscript

We next studied whether central mAChRs, which critically mediate brain cholinergic
pathways and vagus nerve activation21, are required for the anti-inflammatory effect of
GAL. Pretreatment with atropine methyl nitrate (AMN), a mAChR antagonist that does not
cross the BBB, failed to alter the beneficial effects of GAL on colitis (Figure 3). In contrast,
pretreatment with atropine sulfate (AS), a mAChR antagonist that penetrates the BBB,
abrogated the suppressive GAL effect on colitis development (Figure 3). No significant
differences were detected in colonic IL-10 levels (Supplementary Figure 1A). Neither AMN
nor AS alone significantly modified the expression of colitis. These results indicate that the
anti-inflammatory effects of GAL in the context of colitis are mediated through a brain
mAChR-dependent mechanism. Although the presence of mAChRs has been reported on
immune cells19, our data indicate that direct modulation of peripheral mAChRs has no
significant effect on the magnitude of colonic inflammation. In the context of DNBS colitis,
results were similar for MPO activity (Supplementary Figure 2A). However AS and AMN
treatments resulted in a slight, but statistically significant decrease in colonic IL-1β levels
(Supplementary Figure 2B).

Author Manuscript

Central administration of mAChR ligands attenuates the severity of colitis and inhibits
colonic inflammation
As central mAChRs are important in mediating the effects of GAL, we further assessed the
regulatory involvement of these receptors in the context of colitis. Previously, a role for
M1mAChR activation and M2mAChR inhibition in the regulation of inflammation during
endotoxemia has been described20. Accordingly, we performed experiments with mice
subjected to i.c.v. infusions of specific mAChR ligands. Treatment with the M1mAChR
agonist (McN-A-343; 5 ng/kg/day) starting one day before induction of DSS-colitis
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decreased the macroscopic score, the MPO activity, serum CRP levels, the colonic tissue
pro-inflammatory cytokine levels (Figure 4) and the histological score (Figure 2E, G). No
significant differences were detected in colonic IL-10 levels (Supplementary Figure 1B).

Author Manuscript

Then, we examined the anti-inflammatory efficacy of an alternative approach of central
cholinergic activation. Central ACh release is negatively regulated by the presynaptic
M2mAChR autoreceptor35, 36. Therefore, we studied the efficacy of i.c.v. infusion of the
M2mAChR antagonist methoctramine (MTT,5 ng/kg/day). MTT administration, initiated
one day before induction of colitis resulted in comparable significant decrease of colitis
severity (Figure 4, 2F,G). We also demonstrated the beneficial effect of both treatments in
the context of DNBS colitis (Supplementary Figure 3). These findings highlight the specific
regulatory role of central mAChRs in suppressing colitis pathogenesis and are in line with
the previously reported anti-inflammatory effects of these two drugs in the context of
endotoxemia20.
Central cholinergic disease-alleviating and anti-inflammatory efficacy is mediated through
vagus and splenic nerve signaling and the release of ACh in the spleen

Author Manuscript

To study whether the beneficial effects of central cholinergic activation in the context of
colitis depend on the vagus nerve-to spleen axis we performed a series of experiments with
mice subjected to vagotomy (VXP), splenic neurectomy (NRX) and/or splenectomy (SPX).
VXP significantly exacerbated the severity of colitis (Figure 5 & Supplementary Figure 4),
thus confirming our previously reported findings37. SPX did not alter the development of
colitis; however the absence of the spleen abolished the deleterious effect of VXP (Figure 5
& Supplementary Figure 4). The beneficial effects of GAL on disease severity and
inflammation were abolished in mice with VXP, SPX, or VXP and SPX (Figure 5 &
Supplementary Figure 4). NRX resulted in comparable to VXP exacerbation of disease
severity (Figure 5 & Supplementary Figure 4). These effects were abolished in mice
simultaneously subjected to SPX (Figure 5 & Supplementary Figure 4). Furthermore, the
beneficial effects of GAL were abrogated in mice with NRX, SPX or NRX and SPX (Figure
5, Supplementary Figure 4). No effect of these manipulations was observed on colonic IL-10
levels (Supplementary Figure 1).

Author Manuscript

In addition, beneficial effects of the M1mAChR agonist McN-A-343 i.c.v. infusion in the
context of colitis were abolished in the absence of an intact vagus nerve or splenic nerve, or
in mice with SPX (Supplementary Figure 5). Previously, vagus nerve activation functionally
associated with signaling along the splenic nerve has been demonstrated to result in an
increase of ACh in the spleen25. Therefore, we next examined the effects of GAL and McNA-343 treatments on splenic ACh levels and the mediating role of the vagus nerve and the
splenic nerve. GAL and McN-A-343 treatments were associated with a significant increase
in ACh levels in the spleen of sham-operated control mice with DSS colitis (Figure 6). ACh
levels in the VXP and the NRX group were significantly lower as compared to shamoperated controls in mice with DSS colitis and VXP and NRX significantly abolished the
increase in splenic ACh release caused by GAL or McN-A-343 treatments (Figure 6).
Together, these results demonstrate that neural signaling through the vagus nerve-to spleen
axis is required for central cholinergic activation to alleviate colitis.
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Central cholinergic activation decreases splenic CD11C+ cell cytokine production
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To gain further insight into the cellular mechanisms mediating cholinergic antiinflammatory effects on colitis we studied the role of splenic CD11C+ cells. IL-12p40, IL-1β
and IL-6 levels in the splenic CD11C+ cells-culture supernatant from colitic GAL-treated
(Figure 7) were significantly decreased as compared to colitic non-treated groups.
Conversely, VXP or NRX increased IL-12p40, IL-1β and IL-6 levels (Figure 7) and no
beneficial effect of GAL (Figure 7) treatment was found in the absence of an intact vagus or
splenic nerve. The cell viability in non-colitic condition was 99+2.4%; however in all the
groups treated with DSS the cell viability decreased to 82+3.2%. We next performed ex vivo
experiments to highlight the role of the α7nAChR in mediating cholinergic antiinflammatory effects in spleen. Splenic CD11C+ cells were isolated from colitic mice
subjected to sham-operation, VXP or NRX and a treatment with GAL (i.p.). Then, these
cells were treated ex vivo with GTS-21 (a specific α7nAChR agonist). At all conditions the
addition of GTS-21 in the culture medium significantly decreased IL-12p40, IL-1β and IL-6
levels production (Figure 7). We also demonstrated the beneficial effects of cholinergic
treatments in the context of DNBS colitis (Supplementary Figure 6). Apart from being an
AChE inhibitor, GAL has properties of an allosteric positive modulator of nicotinic,
including α7nAChR38. Therefore, we evaluated the possibility that stimulation of the
α7AChR on splenic CD11C+ cells by GAL might contribute to anti-inflammatory effects.
Splenic CD11C+ cells isolated from non-colitic mice were activated with LPS and treated
with GAL or vehicle ex vivo. We did not observe any significant effect of GAL (100 μM) on
IL-12p40, IL-1β and IL-6 levels (440±23 vs 435±41, 640±78 vs 712±65, 910±54 vs 876±44
pg/ml respectively) in these settings.
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To further assess the effects of in vivo treatments and surgeries we next examined the
surface expression of MHC II and costimulatory molecules (CD40, CD86, CD80). In the
absence of colitis, naïve splenic CD11C+ cells expressed low levels of CD40, CD86, CD80
and moderate levels of MHC II at cell surface. Upon activation of colonic inflammation, the
surface expression of MHC II was upregulated (Figure 8A), and such upregulation was
further augmented by VXP and NRX. CD40, CD80 and CD86 expressions were not
modified (Figure 8B–D). GAL treatment decreased the level of MHC II in the splenic
CD11C+ cells isolated from mice with colitis, and no beneficial effect of GAL treatment was
found in the absence of an intact vagus or splenic nerve (Figure 8A). In the absence of
colitis no significant modification of the expression of the different markers was determined
in the different groups (data not shown).

Discussion
Author Manuscript

The results of this study clearly indicate that central cholinergic activation by AChE
inhibitors or selective mAChR ligands results in a decreased susceptibility to experimental
colitis. These protective effects are dependent on vagus nerve and splenic nerve signaling,
which is mediated at a cellular level through cholinergic suppression of splenic DC
activation.
In line with previous findings indicating a role for brain mAChRs in the central activation of
the vagus nerve-mediated cholinergic anti-inflammatory pathway20 exogenous GAL failed
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to reduce the severity of colitis in mice with pharmacological blockage (by AS) of central
mAChRs. The lack of effects of AS or AMN alone on colitis severity suggests that the basal
levels of ACh are not associated with protective effects through mAChR-mediated
mechanisms. Furthermore, the therapeutic efficacy of McN-A-343 and MTT highlight
exploiting central cholinergic activation by M1mAChR agonists or M2mAChR antagonists
as novel approaches to alleviate colitis. While it is known that peripheral cholinergic
activation may have some effect on colitis39, in our study we found no evidence for a
significant role of peripheral mAChRs in mediating protective cholinergic effects in the
context of this experimental plan. Our findings that the effects of GAL and McN-A-343 are
mediated through activation of the vagus nerve-based cholinergic anti-inflammatory
pathway are consistent with experimental evidence pointing to a protective role of the vagus
nerve against acute colitis in animal models4, 40, 41. The disease-alleviating and antiinflammatory effects of both GAL and McN-A-343 treatments were abrogated in mice with
VXP, NRX or mice with splenectomy. These results are in line with data demonstrating that
vagus nerve stimulation fails to protect against septic shock in rats subjected to common
celiac branch VXP, splenectomy or NRX25, 42. Both therapeutics (GAL and McN-A-343)
increased splenic ACh levels in mice and this effect was not observed in mice with VXP and
NRX, indicating that the protective cholinergic effect is dependent on an interaction between
the vagus nerve and spleen. These results are consistent with recent observations that splenic
ACh is released after vagus nerve activation, which can result in a paracrine effect on
antigen presenting cells and anti-inflammatory effect during endotoxemia25. Thus, our
results identify a vagus nerve –to spleen axis as an important mediator of the central
cholinergic regulation of colitis severity. The importance of our findings was additionally
substantiated by the similar profile of results in a DNBS-model, which broadens the
therapeutic implications of cholinergic modalities in the regulation of intestinal
inflammation.
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Although previous observations clearly implicate peritoneal macrophages4, 43 and splenic T
cells44 in the context of the cholinergic anti-inflammatory pathway, it was not previously
known whether changes in splenic CD11C+ cell responses play a role in regulating gut
inflammation by cholinergic signaling. Our data demonstrate that activated vagus nerve
signaling affects splenic CD11C+ cells cytokine production and expression of MHC II,
which subsequently may play an important role in regulation of gut inflammation through
the CD4+T cell population. This observation substantiates previous studies related to the
importance of DCs in the context of experimental colitis45 and demonstrating amelioration
of DSS-induced colitis by depletion of DCs after administration of diphtheria toxin in
CD11c-DT receptor transgenic mice17. This is in agreement with clinical data demonstrating
that IBD is characterized by increased expression of IL-12p40, IL-1β and IL-6 proinflammatory cytokines in the gut and serum46.
Our results indicate that splenectomy does not affect colitis. This observation is in line with
the hypothesis that appendicular lymphoid tissue, but not the spleen, contributes to the
development of colitis47. It also suggests that while the gut is the site of disease initiation,
the regulation of the cytokine release can be mediated via the spleen. Since the vagus nerve
has a tonic inhibitory activity on the release of pro-inflammatory cytokines such as IL-1β,
IL-6, from the splenic DCs, its surgical interruption enhances the release of these cytokines
Mucosal Immunol. Author manuscript; available in PMC 2014 September 01.
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from the spleen. This consequently results in exacerbation of the disease initiated within the
colon, and is abolished by VXP, NRX or SPX. These findings are in line with the concept of
neural signal modulation of mobile immune cell activation in the spleen48. While transiting
the spleen, immune cells pass through its vascular matrix in proximity to neuronal endings
arising from the splenic nerve. Thus, the inflammatory phenotype of immune cells might
undergo neural modulation so that when exiting the spleen, these cells either fail to be
recruited to zones of inflammation or fail to mediate damage49. This concept has
implications for understanding disease pathogenesis and the role of neural regulation in
inflammatory conditions initiated or mediated by the trafficking and accumulation of
inflammatory cells in peripheral tissues. Although it is theoretically possible that mesenteric
lymphoid or lamina propria DCs may also be involved in mediating cholinergic effects in
the context of colitis, our findings clearly point to a role of splenic CD11C+ cells in this
regulation. However, the possible contribution of other circulating immune cell (i.e.
granulocytes) might also be considered. This regulation could be dysfunctional in the
context of IBD with autonomic impairment. Therefore, stimulating vagus nerve activity may
contribute to restoring the anti-inflammatory neuro-immune regulation at the level of the
spleen.
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We have further highlighted the mediating role of the α7AChR on splenic CD11C+ cells; a
specific α7AChR agonist down-regulated ex vivo IL-12p40, IL-6 and TNF-a release. This
corroborates data demonstrating that in vitro immature spleen DCs that mature in a nicotinic
environment manifest lower endocytic and phagocytic activities50. In vitro mature spleen
DCs that are exposed to nicotine produce decreased levels of IL-12p40 and displayed
reduced ability to induce T-Cell responses51. Moreover, our data do not support the
possibility that galantamine may act as an allosteric modulator on the α7AChR on splenic
CD11C+ cells to directly affect their activation.
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It should be acknowledged that apart from the spleen the vagus nerve targets the proximal
colon. Therefore, it is theoretically possible that alterations in the inflammatory state in the
vagus nerve-innervated proximal colon affect the enteric nervous system activity in the
remainder of the colon52, which in turn may result in alterations in neurotransmitter release
and suppression of inflammation. This may also account for the effect of vagus nerve
signaling on colitis observed in this and other studies 4, 40. However, in our study we did not
observe significant effects of GAL or McN-A-343 in the absence of the spleen. It is also
conceivable that other factors may contribute to the beneficial effects of these cholinergic
treatments on colitis. A dominant sympathetic drive, which can simultaneously occur with
impaired vagus nerve activity, has been associated with enhanced colonic inflammation53.
In addition, vagotomy alters lymphocyte trafficking54 and the number of mast cells in the
gut55 and influences gut physiology56. Therefore, alteration of these parameters may also
contribute to changes in colitic severity as a result of cholinergic, vagus nerve-mediated
stimulation. Furthermore, the fact that we did not observe significant effects of GAL or
McN-A-343 on IL-10 levels suggests that alterations in anti-inflammatory cytokine levels do
not play a role in mediating the beneficial effects of cholinergic modalities on colitis
severity. This confirms previous data indicating no role of IL-10 in mediating cholinergic
regulation of immune responses in models of endotoxemia and colitis28, 43. In addition,
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cholinergic treatments did not alter the stool consistency in control mice, indirectly pointing
to a lack of significant effect on gut physiology.
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Our findings prompt close consideration of the relationship between brain cholinergic
activation and disease activity in patients with colonic inflammation and have important
clinical relevance. Patients with colonic inflammatory conditions might be selected for novel
treatment strategies including: 1) Centrally-acting AChE inhibitors, which are already
clinically approved for the treatment of Alzheimer’s disease; 2) highly selective muscarinic
receptor agonists or antagonists6, which are being actively developed for the treatment of
Alzheimer’s disease and other neurodegenerative disorders; and 3) electrical vagus nerve
stimulation, which is now being used for the treatment of refractory depression and
epilepsy57. The therapeutic potential of alternative techniques targetting an increase of
efferent vagus nerve outflow, such as acupuncture58, 59, and zen60, 61 may also be studied in
the context of colonic inflammation.
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ACh

acetylcholine

α7nAChR

alpha7 nicotinic acetylcholine receptor

AMN

atropine methyl nitrate

AS

atropine sulfate

CD

Crohn’s disease

CRP

C-reactive protein

DAI

disease activity index

DCs

dendritic cells

DNBS

2,4 dinitrobenzene-sulfonic acid

DSS

dextran sodium sulfate

GAL

galantamine

IBDs

inflammatory bowel diseases
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i.c.v

intracerebroventricular

IL

interleukin

INF

interferon

LPS

lipopolysaccharide

MLA

methyllycaconitine

MPO

myeloperoxidase

MTT

methoctramine

mAChR

muscarinic acetylcholine receptor

NRX

splenic neurectomy

SPX

splenectomy

TNF

tumor necrosis factor

UC

ulcerative colitis

VXP

vagotomy and pyloroplasty
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Figure 1. Galantamine (GAL) alleviates the severity of dextran sulphate sodium (DSS)-induced
colitis

Author Manuscript

GAL (6 days, i.p.) treatment was started one day prior to colitis induction. A: Disease
activity index; B: Macroscopic scores; C: Colonic myeloperoxidase (MPO) activity; D:
Serum C-reactive protein (CRP). Values are shown as means±SEM. Samples were collected
on day 5 post-DSS; mice per group ≥8. aP<0.05 as compared to saline DSS-treated
group, bP<0.05 as compared to control (H2O)-treated group.
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Figure 2. Centrally-acting acetylcholinesterase inhibitors and mAChR ligands alleviate the
severity of dextran sulphate sodium (DSS)-induced colitis
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Appearance of a colon in mice A: in absence of colitis (control group); B: in mice with
DSS-induced colitis; C: in galantamine (GAL) (4mg/kg, i.p. for 6 days)-treated mice with
DSS-induced colitis D: in Huperzine A (Hup A) (0.4mg/kg, i.p. for 6 days)-treated mice
with DSS-induced colitis E: in McN-A-343 (M1mAChR agonist) (5 ng/kg/day, i.c.v., for 6
days)-treated mice with DSS-induced colitis F: in methoctramine (MTT, M2mAChR
antagonist) (5 ng/kg/day, i.c.v., for 6 days)-treated mice with DSS-induced colitis G:
Histological score; values are shown as means±SEM. Samples were collected on day 5 postDSS; mice per group ≥8. aP<0.05 as compared to saline DSS-treated group, bP<0.05 as
compared to control (H2O)-group. Hematoxylin and eosin staining, 100X magnifications.
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Figure 3. Galantamine (GAL) effects in dextran sulphate sodium (DSS)-induced colitis are
mediated through central mAChRs
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Atropine methyl nitrate (AMN, a mAChR antagonist that does not cross the blood-brain
barrier) (4mg/kg, i.p. for 6 days) or atropine sulfate (AS, a mAChR antagonist that crosses
the blood-brain barrier) were administered as a single daily injection 20 min prior to every
GAL administration (4mg/kg, i.p., for 6 days). A: Macroscopic score; B: Colonic
myeloperoxidase (MPO) activity; C: Serum C-reactive protein (CRP); D: Colonic
Interleukin (IL)-1β amount; E: Colonic IL-6 amount; F: Colonic tumor necrosis factor
(TNF)-α amount. Values are shown as means±SEM. Samples were collected on day 5 postDSS; mice per group ≥8. aP<0.05, compared to non DSS-treated group (control, H20)
respectively, bP<0.05 as compared to vehicle DSS-treated group respectively, cP<0.05 as
compared to GAL-DSS-treated group.
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Figure 4. Central administration of a M1mAChR agonist or a M2mAChR antagonist alleviates
the severity of dextran sulphate sodium (DSS)-induced colitis
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McN-A-343 (M1mAChR agonist) or methoctramine (MTT, M2mAChR antagonist) (5
ng/kg/day, i.c.v., for 6 days) treatments were started one day before induction of colitis. A:
Macroscopic score; B: Colonic myeloperoxidase (MPO) activity; C: Serum C-reactive
protein (CRP); D: Colonic Interleukin (IL)-1β amount; E: Colonic IL-6 amount; F: Colonic
tumor necrosis factor (TNF)-α amount. Values are shown as means±SEM. Samples were
collected on day 5 post-DSS; mice per group ≥8. aP<0.05, compared to non DSS-treated
group (control, H20) respectively, bP<0.05 as compared to vehicle DSS-treated group.
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Figure 5. Galantamine’s effects in mice with dextran sulphate sodium (DSS)-induced colitis are
mediated through vagus nerve and splenic nerve signaling to the spleen
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Vagotomy (VXP) and/or splenectomy (SPX), splenic neurectomy (NRX) and/or
splenectomy (SPX) were performed 10 days prior to initiating galantamine (4 mg/kg/day,
i.p.) treatment and/or colitis induction as described in Material and Methods. *Sham
represents data obtained in sham SPX mice, because no significant differences were
determined between this group and any other sham group of animals; A: Macroscopic score;
B: Colonic myeloperoxidase (MPO) activity; C: Serum C-reactive protein (CRP); D:
Colonic Interleukin (IL)-1β amount; E: Colonic IL-6 amount; F: Colonic tumor necrosis
factor (TNF)-α amount. Values are shown as means±SEM. Samples were collected on day 5
post-DSS; mice per group ≥8. aP<0.05 as compared to sham-saline-DSS-treated
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group, bP<0.05 as compared to VXP-DSS-treated group or NRX-DSS-treated
group, cP<0.05 as compared to sham-GAL-DSS-treated group.

Author Manuscript
Author Manuscript
Author Manuscript
Mucosal Immunol. Author manuscript; available in PMC 2014 September 01.

Ji et al.

Page 22

Author Manuscript
Author Manuscript
Figure 6. Cholinergic treatments with galantamine (GAL) or McN-A-343 result in increased
splenic acetylcholine (ACh) levels, mediated through vagus nerve and splenic nerve signaling
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Vagotomy (VXP) and/or splenic neurectomy (NRX) were performed 10 days prior to GAL
(4mg/kg/day, i.p. for 6 days) or McN-A-343 (5ng/kg/day, i.c.v., for 6 days) treatments and
splenic ACh levels were analyzed as described in Material and Methods. Splenic ACh levels
were determined on day 5 post-colitis induction with dextran sulphate sodium (DSS). In
colitic control condition, the level of ACh was 1845±85μM/spleen. Values are shown as
means±SEM, 3 independent experiments with 4 mice per group. aP<0.05 as compared to
control sham-DSS-treated group, bP<0.05 as compared to sham GAL-DSS-treated
group, cP<0.05 as compared to sham MCN-A-343-DSS-treated group.
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Figure 7. Effects of cholinergic treatment on splenic CD11c+ cells cytokine production in the
context of dextran sulphate sodium (DSS)-induced colitis
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A: Interleukin (IL)-12p40, IL-1β and IL-6 production from dendritic cells. Splenic CD11c+
cells were isolated from galantamine (GAL, 4 mg/kg/day, i.p. for 6 days)-treated groups of
colitic mice subjected to sham-operation, vagotomy (VXP) or splenic neurectomy (NRX) on
day 5 post-colitis induction. Splenic CD11c+ cells were also isolated from groups of colitic
mice subjected to sham-operation, vagotomy (VXP) or splenic neurectomy (NRX) and
incubated ex vivo with GTS-21 (a specific α7nAChR agonist, 100 μM). IL-12p40, IL-1β and
IL-6 was measured in media at 24h following treatments. Values are shown as means±SEM,
3 independent experiments with 4 mice per group. aP<0.05 as compared to DSS control
group, bP<0.05, n=8.
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Figure 8. Effect of cholinergic treatments with galantamine (GAL), vagotomy and neurectomy
on splenic CD11c+ cells phenotype in the context of dextran sulphate sodium (DSS)-induced
colitis

Using CD11c+ MACS positive selection, splenic CD11c+ cells were isolated from
galantamine (GAL, 4 mg/kg/day, i.p. for 6 days)-treated or vehicle groups of colitic mice
subjected to sham-operation, vagotomy (VXP) or splenic neurectomy (NRX) on day 5 postcolitis induction. Splenic CD11c+ cell phenotype as characterized by median fluorescence
intensity (% of Max) A: MHC II (Alexa-647), B: CD40 (FITC), C: CD80 (PE) and D:
CD86 (V450) surface expression. Representative results from n=4 per group are shown.
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